المؤلفون: Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, Juan W, Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., Klümpen, H. J., Chang, H. M., Chen, L. T., Tabernero, J., Oh, D. Y., Mahipal, A., Moehler, M., Mitchell, E. P., Komatsu, Y., Masuda, K., Ahn, D., Epstein, R. S., Halim, A. B., Fu, Y., Salimi, T., Wacheck, V., He, Y., Liu, M., Benhadji, K. A., Bridgewater, J. A.

المساهمون: Department of Medicine, Stanford University School of Medicine, and the Stanford Cancer Center, Palo Alto and the University of California, San Francisco, San Francisco

Relation: https://dx.doi.org/10.1056/NEJMoa2206834; Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma. The New England journal of medicine. 2023 Jan 19;388(3):228-39. PubMed PMID: 36652354. Epub 2023/01/19. eng.; http://hdl.handle.net/10541/626008; New England Journal of Medicine

الاتاحة: http://hdl.handle.net/10541/626008
https://doi.org/10.1056/NEJMoa2206834

المؤلفون: Goyal, L., Meric-Bernstam, F., Hollebecque, A., Morizane, C., Valle, Juan W, Karasic, T. B., Abrams, T. A., Kelley, R. K., Cassier, P. A., Furuse, J., Klumpen, H. J., Chang, H. M., Chen, L. T., Komatsu, Y., Masuda, K., Ahn, D. H., Li, K., Benhadji, K. A., Wacheck, V., Bridgewater, J. A.

المساهمون: Mass General Cancer Center, Harvard Medical School, Boston, MA

Relation: https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.4009; Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301177.; http://hdl.handle.net/10541/625800; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/625800
https://doi.org/10.1200/JCO.2022.40.16_suppl.4009

المؤلفون: Furuse, J., Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, Juan W, Morizane, C., Karasic, T. B., Abrams, T. A., Kelley, R. K., Cassier, P. A., Klumpen, H. J., Uboha, N., Mahipal, A., Mitchell, E., Ahn, E., Chang, H. M., Masuda, K., He, Y., Benhadji, K. A., Bridgewater, J. A.

المساهمون: Department of Medical Oncology, Kyorin University Hospital, Tokyo, Japan

Relation: https://dx.doi.org/10.1016/j.annonc.2020.10.137; Furuse J, Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, et al. 116MO Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2. Annals of Oncology. 2020;31:S1288-S9.; http://hdl.handle.net/10541/623692; Annals of Oncology

الاتاحة: http://hdl.handle.net/10541/623692
https://doi.org/10.1016/j.annonc.2020.10.137

المؤلفون: Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, Juan W, Morizane, C., Karasic, T. B., Furuse, J., He, Y. H., Soni, N., Benhadji, K. A., Bridgewater, J. A.

المساهمون: Massachusetts General Hospital, Boston, MA

Relation: Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. Journal of Clinical Oncology. 2020;38(15); http://hdl.handle.net/10541/623383; Journal of Clinical Oncology

الاتاحة: http://hdl.handle.net/10541/623383

المؤلفون: Goyal, L., Meric-Bernstam, F., Hollebecque, A., Valle, Juan W, Morizane, C., Karasic, T. B., Abrams, T. A., Furuse, J., Kelley, R. K., Cassier, P. A., Klümpen, H. J., Chang, H. M., Chen, L. T., Tabernero, J., Oh, D., Mahipal, A., Moehler, M., Komatsu, Y., Ahn, D. H., Epstein, R. S., Halim, A. B., Wacheck, V., He, Y. H., Liu, M., Benhadji, K. A., Bridgewater, J. A., Invest, F. C. S.

المساهمون: Division of Cancer Sciences, University of Manchester, Manchester, UK

Relation: Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, et al. Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer. FUTURE ONCOLOGY. 2024 2024 JUN 17.; http://hdl.handle.net/10541/627084; Future Oncology

الاتاحة: http://hdl.handle.net/10541/627084
https://doi.org/10.1080/14796694.2024.2364504

المؤلفون: Perez, K, Cleary, J. M., Karasic, T. B., Raghaven, S., Rahma, O. E., Nowak, J. A., Borazanci, E. H., Downes, Michael, Drebin, JeffreyA, Tuveson, D. A., Ting, D. T., Moffitt, R. A., Yeh, J. J., Aguirre, A. J., Evans, R., Von Hoff, D. D., Odwyer, P. J., Wolpin, B. M.

مصطلحات موضوعية: pancreatic cancer, Vitamin D receptor

Relation: Perez, K, Cleary, J. M., Karasic, T. B., Raghaven, S., Rahma, O. E., Nowak, J. A., Borazanci, E. H., Downes, Michael, Drebin, JeffreyA, Tuveson, D. A., Ting, D. T., Moffitt, R. A., Yeh, J. J., Aguirre, A. J., Evans, R., Von Hoff, D. D., Odwyer, P. J., Wolpin, B. M. (February 2020) Vitamin D receptor agonist paricalcitol plus gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer. Journal of Clinical Oncology, 38 (4). ISSN 0732-183X

الاتاحة: http://repository.cshl.edu/id/eprint/39504/
https://ascopubs.org/toc/jco/38/4_suppl

المؤلفون: Goyal, L., Meric-Bernstam, F., Hollebecque, A., Morizane, C., Valle, Juan W, Karasic, T. B., Abrams, T. A., Kelley, R. K., Cassier, P., Furuse, J., Klumpen, H. J., Chang, H. M., Chen, L. T., Komatsu, Y., Masuda, K., Ahn, D., He, Y. H., Soni, N., Benhadji, K. A., Bridgewater, J. A.

المساهمون: Massachusetts General Hospital, Boston

Relation: https://dx.doi.org/10.1158/1538-7445.AM2021-CT010; Goyal L, Meric-Bernstam F, Hollebecque A, Morizane C, Valle JW, Karasic TB, et al. Abstract CT010: Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements. In: Clinical Trials. American Association for Cancer Research; 2021.; http://hdl.handle.net/10541/624619; Cancer Research

الاتاحة: http://hdl.handle.net/10541/624619
https://doi.org/10.1158/1538-7445.AM2021-CT010